Tender detail
Non-exclusive rebate agreement for medicines containing apixaban
Summary
DAK-Gesundheit intends to conclude rebate agreements for medicines containing apixaban (ATC B01AF02) with as many interested pharmaceutical companies as possible. The agreements will run from 1 December 2026 to 30 November 2028, with an option to extend for one 12-month period, and will end when a new exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.